Spondyloarthritis & psoriatic arthritis
Improvements in Patient‐Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial
Authors' conclusion
Deucravacitinib groups demonstrate significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA
Study context
- Population
- Patients with active psoriatic arthritis (PsA)51.2% female
- Participants
- 203 patients
- Comparison
- Deucravacitinib 6 mg or 12 mg QD vs placebo for 16 weeks
Methodological detailsphase 2, double-blind, 1:1:1 randomisation, placebo-controlled
- Phase 2
- Double-blind
- 1:1:1 randomisation
- Placebo-controlled
Secondary outcomes
| Outcome | Adjusted mean difference (95% CI) | P value | |
|---|---|---|---|
| Key secondary: HAQ-DI change from baseline, adjusted MD vs placebo · week 16Deucravacitinib 6 mgvs Placebo | −0.26 (−0.42 to −0.10) | P = 0.0020 | |
| Key secondary: HAQ-DI change from baseline, adjusted MD vs placebo · week 16Deucravacitinib 12 mgvs Placebo | −0.28 (−0.45 to −0.12) | P = 0.0008 | |
| Key secondary: SF-36 PCS change from baseline, adjusted MD vs placebo · week 16Deucravacitinib 6 mgvs Placebo | 3.3 (0.9–5.7) | P = 0.0062 | |
| Key secondary: SF-36 PCS change from baseline, adjusted MD vs placebo · week 16Deucravacitinib 12 mgvs Placebo | 3.5 (1.1–5.9) | P = 0.0042 | |
| −50510Difference (linear scale) |
Additional patient-reported outcomes (PROs) (fatigue, pain, mental health): MCID and normative values · week 16
- MCID at week 16 reported for all PROs with either dose of deucravacitinib
- Improvements of MCID or to normative values reported by more patients receiving deucravacitinib than placebo
Original publication
Improvements in Patient‐Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial. Arthritis Care Res (Hoboken). Published 7 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →